Precancerous colon polyps in patients with Lynch syndrome exhibit immune activationApril 16, 2018
HOUSTON - Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation well before cancer development, according to research from The University of Texas MD Anderson Cancer Center. The preclinical research challenges traditional models of cancer immune activation and suggests immunotherapy may be useful for colorectal cancer prevention in certain high-risk groups.
The findings, published in JAMA Oncology, will be presented today at the American Association for Cancer Research Annual Meeting 2018 in Chicago by Kyle Chang, graduate research assistant.
Immune checkpoint inhibitors targeting PD-1, such as pembrolizumab and nivolumab, have been successful in treating colorectal cancers with deficiencies in DNA mismatch repair (MMR). These tumors accumulate large numbers of genetic mutations and mutant proteins, or neoantigens, which are thought to stimulate an immune response, making them more susceptible to checkpoint blockade therapy.
"Our question was how this worked in premalignancy," said senior author Eduardo Vilar-Sanchez, M.D., Ph.D., assistant professor of Clinical Cancer Prevention and Gastrointestinal (GI) Medical Oncology. "Can we apply checkpoint inhibitors or checkpoint inhibitor strategies to prevent MMR-deficient colorectal cancer?"
Lynch syndrome (LS), which is caused by inherited mutations in MMR, provides the perfect context in which to study early immune activation and explore the potential use of checkpoint inhibitors in a prevention setting, explained Vilar-Sanchez. Over 1 million people in the U.S. are affected by LS, the most common hereditary colorectal cancer syndrome.
In the study, the researchers analyzed gene expression to characterize the immune profile in 11 polyps and three early-stage tumors from 14 patients with LS. As a control, the researchers also analyzed 17 polyps from patients with Familial Adenomatous Polyposis (FAP), a hereditary colorectal cancer syndrome which does not exhibit MMR deficiencies.
The resulting profiles revealed increased expression of several markers of immune activation, including CD4 T-cells, proinflammatory molecules and checkpoint molecules, such as PD-L1 and LAG-3, in LS polyps compared to FAP polyps. However, contrary to traditional models of immune activation, the observed immune profiles were independent of the rate of mutations or neoantigens present in the sample.
"To our surprise, our findings don't follow the standard model. The majority of premalignant lesions do not have an excessive increase in mutations or neoantigens," said Vilar-Sanchez. "However, we observed there is already immune activation, meaning the activation precedes the development of the mutations."
The findings suggest a baseline level of immune activation exists in precancerous polyps, which may prime them for susceptibility to checkpoint blockade, explained Vilar-Sanchez.
Future work will be necessary to clarify the mechanism by which this immune activation occurs, as the current study was observational in nature. The researchers hope to initiate clinical studies to investigate the use of checkpoint blockade strategies for preventing colorectal cancer in high-risk groups, such as those with LS.
"Lynch syndrome patients have a strong immune activation in the colon, and that immune activation can be exploited for preventive purposes," said Vilar-Sanchez. "I think our data provide the information needed to launch studies to use checkpoint inhibition in the setting of prevention."
This work also was supported by the National Cancer Institute (R21 CA208461, R01 CA219463, R25T CA057730, P30 CA016672, K12 CA088084), a gift from the Feinberg Foundation, and The V Foundation For Cancer Research Scholar Grant.
In addition to Vilar-Sanchez, MD Anderson authors include: Kyle Chang, Laura Reyes-Uribe, M.D., Ester Borras, Ph.D., Erick Riquelme, Ph.D., Reagan Barnett, Ph.D., and Ernest Hawk, M.D., all of Clinical Cancer Prevention; Melissa Taggart, M.D., Pathology; F. Anthony San Lucas, Ph.D., Epidemiology; Nancy You, M.D., Surgical Oncology; Jason Roszik, Ph.D., Melanoma Medical Oncology and Genomic Medicine; Paul Scheet, Ph.D., Epidemiology; Scott Kopetz, M.D., Ph.D., GI Medical Oncology; Patrick Lynch, M.D., J.D, Gastroenterology; and Florencia McAllister, M.D., Clinical Cancer Prevention and GI Medical Oncology. Additional authors include: Guido Leoni, Ph.D., and Maria Catanese, Ph.D., Nouscom SRL, Rome; Federica Mori, ReiThera SRL, Rome; Maria G. Diodoro, M.D., Regina Elena National Cancer Institute, Rome; and Alfred Nicosia, Ph.D., of Nouscom SRL, Rome, CEINGE and University of Naple Federico II, Naples, Italy.
University of Texas M. D. Anderson Cancer Center
Related Lynch Syndrome Articles:
Raising the age limit for routine genetic testing in colorectal cancer could identify more cases of families affected by Lynch syndrome, a condition that accounts for around 5 percent of all colon cancers.
A new review investigates the effects of avocados on different components of metabolic syndrome, which is a clustering of risk factors including high blood sugar, cholesterol, blood pressure, and body mass index.
In a new paper, researchers at University of California San Diego School of Medicine, along with colleagues in Brazil and Spain, describe the phenotypic spectrum or set of observable characteristics of congenital Zika (ZIKV) syndrome, based upon clinical evaluations and neuroimaging of 83 Brazilian children with presumed or confirmed ZIKV congenital infections.
The name of the gene is Armc5, for Armadillo repeat containing 5.
Although our genes normally come in pairs but sometimes one of them is missing (haploinsufficiency) leading sometimes to serious diseases.
Columbia University researchers discovered a new neurodevelopmental syndrome and the genetic mutation that causes it.
Harvard Stem Cell Institute researchers have identified a faulty signaling pathway that, when corrected, in mice ameliorates the symptoms of Rett syndrome, a devastating neurological condition.
For the first time, biopsies of patients with irritable bowel syndrome have shown that the nerves in their gut wall respond poorly to a cocktail of inflammatory substances.
Research led by Huda Zoghbi, M.D., at Baylor College of Medicine and HHMI and published today in the journal Nature reveals that the MECP2 Duplication Syndrome is reversible.
All colorectal cancer patients should undergo tumor testing to see if they carry Lynch syndrome, the most common inherited cause of colorectal cancer, according to a new guideline was published in Gastroenterology, the official journal of the American Gastroenterological Association.
Related Lynch Syndrome Reading:
Lynch Syndrome: Tests, Causes and Treatments
by Joseph Strickland MA (Author), Ellis Green MD (Editor)
Lynch syndrome, usually called hereditary nonpolyposis colorectal cancer (HNPCC), is a kind of inherited cancer of the digestive tract, especially the colon and rectum. Persons with Lynch syndrome have an increased risk of cancers in the stomach, intestine, liver, gallbladder ducts, upper urinary tract, brain, skin, and prostate. If you or ar loved one are suffering from this disorder, this invaluable reference contains everything you need to know about tests, treatments and causes for the syndrome. View Details
My Father's Daughter: A Story of Survival, Life, and Lynch Syndrome Hereditary Cancers
by Lindy Bruzzone (Author)
As a child, Lindy Bruzzone knew how she would "someday" die. It would be from cancer as what occurred with almost everyone in her family up to her generation.
Bruzzone tells the story of an American family coming to America in the early 1600s, through today. Defying the odds of fate while pioneering a new country, the stories Lindy's ancestors leave behind inspire the following generations to endure future challenges of facing hardship and survival.
Lindy shares the fear and uncertainty earlier family members experienced living with an unknown hereditary cancer... View Details
Summer's Complaint: My family's courageous, century-long struggle with a rare genetic cancer syndrome
by Critical Eye Publishing
“I thought there might be something wrong with your mother’s family.”
Those words, spoken by a grandmother to her eleven-year-old granddaughter, sparked a search for answers to a mystery
spanning five generations.
Familial adenomatous polyposis is a rare, genetic cancer predisposition syndrome caused by a deletion mutation in the APC gene on chromosome 5. By the age of fifty, nearly 99 percent of untreated patients will have developed cancer.
This is the dark shadow that has lingered over one Midwestern family since at least 1911, when Mary Regan... View Details
Tendril Living With Lynch Syndrome
by Sarah Gilbert (Author)
A poetry chapbook. View Details
DNA Alterations in Lynch Syndrome: Advances in molecular diagnosis and genetic counselling
by Matjaž Vogelsang (Editor)
Lynch syndrome (LS) is the most common cause of inherited colorectal cancer, a disease with a high mortality rate. An estimated 37,000 of diagnosed colorectal cancer cases worldwide are attributed to Lynch syndrome each year. Intensive cancer screening, with early initiation and frequent follow-up, can reduce colorectal cancer incidence and mortality in LS patients. This book provides an up-to-date overview on the genetic and epigenetic basis of Lynch syndrome. It evaluates clinical features of the disease and critically comments on molecular tools available for identifying mutations... View Details
A Simple Guide To Lynch Syndrome, Diagnosis, Treatment And Related Conditions
Lynch syndrome is an inherited medical disorder that confers a person a higher risk of cancers of the digestive tract, gynecologic tract, and other organs.
In Singapore Lynch syndrome has an estimated incidence of 1 in 300 in women and 1 in 500 in the general population.
People who have Lynch syndrome have a considerably higher danger of forming:
1. Colorectal cancer (CRC),
2. Endometrial (uterine) cancer,
3. Gastric (stomach) cancer,
4. Ovarian cancer,
5. Small bowel (small intestinal) cancer,
6. Pancreatic cancer,
7. Urinary tract cancer (bladder... View Details
NCCN Guidelines for Patients®: Colon Cancer, Version 1.2017
by National Comprehensive Cancer Network® (NCCN®) (Author)
[OFFICIAL CURRENT VERSION] From 27 leading cancer centers united under the National Comprehensive Cancer Network® (NCCN®), comes this essential guide to Colon Cancer. Adapted from clinical treatment guidelines used by physicians and oncology professionals around the world, these NCCN Guidelines for Patients® are packed with the latest information, treatment innovations, and resources about Colon Cancer. Each patient-friendly chapter prepares patients and caregivers to talk with their doctors and make treatment decisions. Let this authoritative handbook be your guide! View Details
An Ohio Businessman's Journey:: My Journey Into Darkness (Volume 1)
by Lawrence DeWitt Jones (Author)
An Ohio Businessman's Journey, "My Journey into Darkness" captures the life--- the good, the bad, and the ugly--of Lawrence "Larry D" DeWitt Jones. Growing up on a tobacco farm in Durham in the late 1950s and 60s, LarryD was inspired by his parents' high levels of trust in and respect for all people, including those neighbors who were members of the Ku Klux Klan. His journey brought him in close associations with members of the Ku Klux Klan, an African American business associate, two African American medical doctors an African American attorney, an Ohio public official who was a purported... View Details
Lynch Syndrome (HNPCC) and Microsatellite Instability Analysis Guidelines - Part 2 (Pt. 2)
by A. Umar (Author)
IOS Press is an international science, technical and medical publisher of high-quality books for academics, scientists, and professionals in all fields.
Some of the areas we publish in:
-Databases and information systems
-All aspects of physics
-The knowledge economy
-Understanding and responding to terrorism
-Computer Sciences View Details
Lynch Syndrome (HNPCC) and Microsatellite Instability (Stand Alone)
by A. Umar (Author), A. Umar (Editor)
Since experimental studies with microsatellite instability (MSI)-positive and -negative cell lines as well as clinical data suggest different responses to chemotherapeutic agents, the assessment of MSI status of the tumors is important. It also serves as a screening method for tumors of the hereditary non-polyposis colorectal cancer (HNPCC) spectrum. In cases of sporadic colorectal cancer there is a growing body of evidence indicating the improved prognosis associated with this group of tumors. Furthermore, failure to recognise familial cancer will have a negative impact on the patient’s... View Details